Guardion Health Science - חוב לטווח קצר של החברה GHSI

Guardion Health Science (GHSI) produces nutraceuticals and vision nutrition, planning to fully wind down operations in 2024 following the divestiture of the Activiva brand and the subsequent distribution of funds. This chart illustrates the market price, where the indicator reaches 0.00, complementing data on stable demand for ophthalmological devices. However, the company's narrow operational profile is currently being adjusted through asset restructuring to transfer capital to strategic partners.

Guardion Health Science (GHSI) bets on evidence-based medicine and the retention of leading ophthalmologists, which requires stable funding for operational cycles. The current value of 0.00 reflects the volume of current liabilities used to measure the business's ability to service loans of up to one year; an analysis of total short-term obligations allows an investor to assess liquidity risk and the probability of breaching covenants critical to the development of scientific research.